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Building on previous multicountry surveillance studies of typhoid and others salmonelloses such as the Diseases of the Most 
Impoverished program and the Typhoid Surveillance in Africa Project, several ongoing blood culture surveillance studies are 
generating important data about incidence, severity, transmission, and clinical features of invasive Salmonella infections in sub-Sa-
haran Africa and South Asia. These studies are also characterizing drug resistance patterns in their respective study sites. Each study 
answers a different set of research questions and employs slightly different methodologies, and the geographies under surveillance 
differ in size, population density, physician practices, access to healthcare facilities, and access to microbiologically safe water and 
improved sanitation. These differences in part reflect the heterogeneity of the epidemiology of invasive salmonellosis globally, and 
thus enable generation of data that are useful to policymakers in decision-making for the introduction of typhoid conjugate vac-
cines (TCVs). Moreover, each study is evaluating the large-scale deployment of TCVs, and may ultimately be used to assess post-
introduction vaccine impact. The data generated by these studies will also be used to refine global disease burden estimates. It is 
important to ensure that lessons learned from these studies not only inform vaccination policy, but also are incorporated into sus-
tainable, low-cost, integrated vaccine-preventable disease surveillance systems.
Keywords.  blood culture; enteric fever surveillance; Salmonella Typhi; typhoid fever.
Enteric fever, the collective term for typhoid and paratyphoid 
fevers, describes a systemic infection caused by Salmonella 
enterica serovars Typhi or Paratyphi A, B, or C.  Recent 
estimates suggest that these organisms cause 14.3 million in-
fections (95% confidence interval [CI], 12 500 000–16 300 000) 
and 136 000 deaths (95% CI, 77 000–219 000) annually [1]. 
Invasive nontyphoidal Salmonella (iNTS) disease is caused 
by other Salmonella serovars, most frequently by Salmonella 
Typhimurium, Salmonella Enteritidis, or Salmonella Dublin. 
Invasive nontyphoidal Salmonella disease caused an estimated 
535 000 infections (95% CI, 409 000–705 000) and 77 500 deaths 
(95% CI, 46 400–123 000) in 2017 [2], of which 18 400 were 
Population-based Enteric Fever Studies • cid 2020:71 (Suppl 2) • S103
attributed to human immunodeficiency virus. While improved 
water treatment and sanitation infrastructure have elimin-
ated enteric fever as a public health problem in high-income 
countries, invasive Salmonella infections, which include iNTS, 
remain a public health issue in many low- and lower-middle-
income countries.
A major impediment to understanding the true burden of 
enteric fever and iNTS disease is the lack of appropriately sen-
sitive diagnostics and inconsistent usage of existing tests. Bone 
marrow culture is considered the gold standard for diagnosis of 
typhoid and paratyphoid fever, but given the invasive and chal-
lenging nature of obtaining bone marrow aspirate, it is rarely per-
formed [3]. Often, treating physicians rely on a serological test 
like the Widal test, which has limited utility in endemic settings 
[4]. Blood culture–based diagnostics are recommended for use 
in surveillance of typhoid fever and other invasive Salmonella 
infections by the World Health Organization (WHO) [5], but 
these tests are not available in most low-resource settings, which 
often lack adequate resources and trained personnel required to 
conduct routine blood culture tests [3]; when they are available, 
blood cultures are only 40%–60% sensitive, depending in part 
on the volume of blood collected and prior antibiotic usage, and 
results are not available for several days, so are not useful for 
decisions on empiric therapy [6].
Often, febrile patients will not present to healthcare facilities 
for diagnosis and treatment. Potential deterrents to health-
care seeking include distance to and accessibility of the closest 
healthcare facility, or costs associated with treatment and/or 
hospitalization, combined with ease of access and affordability 
of antimicrobials in the community. As a result, the true number 
of invasive Salmonella infections may be underestimated.
In 2009, the WHO highlighted the need for additional data 
on the burden of invasive Salmonella disease [7]. At that time, 
early estimates of disease burden relied on extrapolation of data 
obtained from surveillance studies conducted in limited geo-
graphical regions, which did not entirely reflect the diversity of 
epidemiological settings in which typhoid is encountered [8]. 
A  historic lack of population-based surveillance studies has 
also contributed to uncertainty around disease burden, partic-
ularly in the African continent. A review of the global burden 
of enteric fever conducted in 2004 showed that only 2 countries 
in Africa had conducted systematic, population-based surveil-
lance between 1954 and 2000 (South Africa and Egypt) [8].
To address the limitations of existing data sets, several sur-
veillance studies have been established over the past decade, 
funded primarily by the Bill & Melinda Gates Foundation and 
the Wellcome Trust. One of the first studies funded was the 
Typhoid Fever Surveillance in Africa Program (TSAP), coor-
dinated by the International Vaccine Institute (IVI). The TSAP 
study demonstrated higher overall incidence  rates of typhoid 
fever in sub-Saharan Africa than previously suspected across 
both rural and urban sites, as well as high incidence  rates of 
iNTS disease across multiple sites [9]. In the years that fol-
lowed, additional surveillance studies were funded to provide 
more data on the burden of disease in diverse epidemiological 
settings and to answer additional questions about clinical fea-
tures of enteric fever, such as the prevalence of severe manifest-
ations of disease and chronic intestinal carriage. These included 
the Severe Typhoid Fever Surveillance in Africa program 
(SETA, IVI); the Surveillance for Enteric Fever in Asia Project 
(SEAP, Sabin Vaccine Institute); the Strategic Typhoid Alliance 
Across Africa and Asia (STRATAA, University of Oxford); 
and the Surveillance of Enteric Fever in India (SEFI, Christian 
Medical College, Vellore). Preliminary data from these studies 
have helped to inform the WHO Strategic Advisory Group of 
Experts’ recommendation for typhoid conjugate vaccine (TCV) 
use in the control of typhoid fever in endemic settings [10], and 
additional data generated by these studies will help direct op-
timal use of TCVs going forward.
Each of these studies has been conducted across mutliple dis-
tinct epidemiological settings and aims to address subtly dif-
ferent questions relating to invasive Salmonella disease burden. 
In this article, we compare the methodological similarities and 
differences between these diverse and complementary studies. 
We also identify early lessons learned and outstanding data 
gaps, and issue recommendations for optimizing and sustaining 
surveillance systems going forward.
STUDY SETTINGS AND METHODS
Severe Typhoid Fever Surveillance in Africa (SETA)
The SETA program builds on the infrastructure established as 
part of the TSAP study to characterize the severity and long-
term effects of typhoid fever and iNTS disease  across Africa. 
TSAP collected blood culture data between 2010 and 2014 and 
generated typhoid incidence rates from sites in 10 sub-Saharan 
African countries: Burkina Faso, Ethiopia, Ghana, Guinea-
Bissau, Kenya, Madagascar, Senegal, South Africa, Sudan, and 
Tanzania. The TSAP results showed a great deal of heteroge-
neity in typhoid incidence across sites, with crude rates ranging 
from 0 to 284 cases per 100 000 person-years, and that there 
is a high burden in both rural and urban sites [9]. SETA sur-
veillance was continued at sites in Madagascar, Burkina Faso, 
and Ghana, and surveillance was extended to include addi-
tional sites in the Democratic Republic of Congo, Ethiopia, and 
Nigeria. These sites were selected based on existing evidence 
of typhoid transmission and clinical microbiology capacity, as 
well as to ensure geographical representativeness of key regions 
within the continent.
Within each of the SETA study areas, patients were recruited 
at healthcare facilities across multiple tiers. Each site included 
a referral hospital, which, to be included in SETA, had to be 
equipped with imaging and surgical capacity to identify and 
treat intestinal perforations, as well as primary or secondary 
healthcare centers, which enrolled less severe febrile subjects 
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using broader enrollment criteria [11]. Each recruitment 
center was assigned a geographic catchment area from which 
a defined population was identified. In all countries apart from 
Madagascar, the catchment area of the primary and/or sec-
ondary centers was “nested” within the catchment area of the 
tertiary center. A  healthcare utilization survey (HCUS) was 
conducted in households randomly selected from the nested 
and broader study catchment areas to estimate incidence rates 
based on the proportion of the population seeking healthcare at 
the respective study facilities.
Screening for study eligibility was systematically conducted at 
all study facilities, including inpatient, outpatient, surgical, and 
emergency wards at referral facilities. To augment case detec-
tion, Salmonella bacteremia detected in SETA laboratories from 
patients who were not enrolled in the study were also included, 
as well as patients with intestinal (ileal) perforation suspected 
to be due to typhoid, from referral hospitals. Intestinal perfora-
tion cases were recruited into the study regardless of whether or 
not the patient resided in the study catchment area. Upon en-
rollment, blood, stool, oropharyngeal, and urine samples were 
collected. Blood was subjected to conventional microbiological 
culture for detection and identification of bacterial pathogens 
as well as other immunological investigations; stool was cul-
tured to assess acute carriage status, and urine was examined 
for antibiotic residues to determine patterns in antimicrobial 
pretreatment.
Patients with blood culture–confirmed Salmonella Typhi, 
Salmonella Paratyphi, and non-Typhi Salmonella serotype in-
fections were recruited into the long-term follow-up com-
ponent of the study. Two healthy household members and 4 
healthy neighborhood controls were enrolled for each case, and 
the entire cohort was followed for 1  year with contact points 
at predefined intervals to collect clinical information, blood 
and stool samples, and cost-of-illness and quality-of-life assess-
ments [11].
Surveillance for Enteric Fever in Asia Project (SEAP)
SEAP is a multicountry, multisite, population-based surveil-
lance study aimed at characterizing the burden of enteric fever 
in South Asia. The project had two phases: phase 1, a retrospec-
tive clinical record review of invasive Salmonella infections, and 
phase 2, a prospective surveillance study. Phase 1 showed that 
Salmonella Typhi and Paratyphoid A was isolated from 0.43% 
to 2% of blood cultures conducted at hospitals in Bangladesh, 
Nepal, Pakistan, and India [12].
The prospective component of the study—initiated in 
October 2016—was conducted at urban and periurban sites 
in Bangladesh, Nepal, and Pakistan. Sites were selected to 
represent diverse communities in South Asia, but choices 
were constrained by the availability of laboratories capable 
of performing high-quality blood cultures. In addition to pa-
tients meeting the inclusion criteria at the hospital sites, the 
SEAP study also recruited enteric fever cases from laboratory 
networks beyond the site hospitals. Blood specimens were 
collected for culture, and a subsample of participants pro-
vided urine samples to test for residual antibiotic metabolites 
to understand antibiotic usage patterns. Data were collected 
on clinical manifestations, markers of severity of illness, com-
plications of illness, and antimicrobial resistance. In addition, 
in collaboration with the US Centers for Disease Control and 
Prevention, an economic study of enteric illness was imple-
mented at all 3 sites [12].
SEAP used a hybrid surveillance approach, adapted from 
Luby et al [13, 14], combining facility-based surveillance with 
an HCUS, administered to a representative subset of house-
holds using a single-stage, cluster design; among patients with 
fever lasting 3 or more days, the proportion that sought care 
for the febrile episode at a study facility was used as an adjust-
ment to the number of enteric fever cases at the facility, for the 
purpose of calculating incidence and disease severity rates. 
Geographic catchment areas were delineated at surveillance 
sites encompassing the majority of suspected enteric fever cases 
identified during phase 1. Catchment areas used administrative 
boundaries so that study staff could easily determine if patients 
resided in the catchment area [12]. SEAP used a hybrid surveil-
lance approach, adapted from Luby et al [13, 14], combining 
facility-based surveillance with an HCUS, which was admin-
istered to a representative subset of households using a single-
stage, cluster design [13]. The proportion within the surveyed 
group who reported a fever lasting 3 or more days and sought 
care for the febrile episode at a study facility was then used as 
an adjustment for care-seeking at the study facilities within the 
catchment area.
Surveillance of Enteric Fever in India (SEFI)
There has been a lack of nationally representative enteric fever 
incidence data in India, as highlighted by a 2016 meta-analysis 
[15]. To fill these data gaps, the SEFI program was established 
by the Christian Medical College, Vellore, and its design was 
developed in collaboration with the Indian Council of Medical 
Research, the Translational Health Sciences and Technology 
Institute, the Indian Academy of Pediatrics, and other public 
health stakeholders [16]. The SEFI team established a 3-tiered 
surveillance system to estimate the age-specific incidence of en-
teric fever in children, examine the heterogeneity of incidence 
in diverse settings  across India, and generate information on 
antimicrobial resistance patterns and cost of illness. Study en-
rollment began in October 2017.
The tier 1 surveillance for estimating the incidence of enteric 
fever in children consists of active, community-based surveil-
lance in 1 rural and 3 urban sites, which  were selected to be 
broadly representative of different geographic settings and pop-
ulation densities. At each of the 4 sites, 6000 children between 
6  months and 15  years are followed each week for 2  years to 
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estimate the age-specific incidence rates of enteric fever in chil-
dren. At least 1 contact each month is in-person and the rest are 
either in-person or by telephone. Parents are also encouraged 
to reach out to the study team if a child has fever in between 
weekly follow-up points, and all participating families are given 
thermometers and diary cards. Any fever of 3 or more consecu-
tive days is considered a suspected case, and the child is referred 
to a study facility on the fourth day of fever, where a blood cul-
ture is performed if the child has had fever in the past 12 hours. 
Risk factors and other demographic data are also collected from 
participating households to permit extrapolation of incidence 
estimates to other similar risk settings [17].
Tier 2 is passive, hospital-based surveillance, which has been 
harmonized across 6 secondary-care facilities in 6 settings (5 
rural and 1 urban) with well-defined catchment populations be-
tween 100 000 and 400 000 each. All patients hospitalized at a 
study facility with a fever are considered eligible. Upon consent, 
a blood culture is collected irrespective of duration of fever or 
temperature. Those with blood culture–confirmed enteric fever 
are followed up for 28 days to capture costs and clinical compli-
cations. Biannual HCUSs are administered to 5000 randomly 
selected households in 100 clusters at each site. These are used to 
determine the probability of seeking healthcare at the study fa-
cility. The population denominators are estimated by projecting 
annual growth rates from the 2011 census for each village in 
the catchment area and validated by reviewing the population 
in the sampled clusters in the HCUS. The tier 2 surveillance 
system was designed to estimate the incidence of severe enteric 
fever (requiring hospitalization) across all age groups.
Tier 3 surveillance is being conducted at 8 laboratories 
linked to tertiary care hospitals. The aims of this component 
of the surveillance system are to generate estimates of the pro-
portion of blood cultures that are positive for Salmonella Typhi 
or Paratyphi A  and to characterize antimicrobial resistance 
patterns. Patients with nontraumatic ileal perforations are also 
enrolled in tier 2 and 3 surveillance and followed up for up to 
90 days for clinical and health economic outcomes.
Strategic Typhoid Alliance Across Africa and Asia (STRATAA)
The STRATAA consortium, which includes key partners from 
the University of Oxford’s Oxford Vaccine Group, the Malawi 
Liverpool Wellcome Trust Clinical Research Programme, 
the International Center for Diarrhoeal Disease Research, 
Bangladesh (icddr,b), and the Oxford University Clinical 
Research Unit (Vietnam and Nepal), has conducted a pro-
spective multicomponent epidemiological study in 3 densely 
populated urban sites in Bangladesh, Nepal, and Malawi [18]. 
This study combines passive febrile illness surveillance with se-
rological surveillance. A baseline population of approximately 
100 000 was established at each site by demographic census. 
Field teams visited each individual house, recording GPS po-
sition and collecting epidemiological data at the household 
and individual level. A  census update was conducted every 
6 months at the Bangladeshi site and at 12 months in Nepal, 
and a final census was conducted at all 3 sites after 2 years. In 
addition, 2 HCUS and water, sanitation, and hygiene surveys 
were performed in each site during the surveillance period to 
generate additional data on healthcare-seeking behavior and 
to investigate potential disease risk factors and transmission 
routes.
Passive surveillance was conducted from June 2016 in re-
ferral hospitals and primary health centers. Patients living 
within the population catchment area who presented to a study 
facility reporting fever of 2  days or longer or having a docu-
mented temperature of ≥ 38°C were enrolled and consented 
and blood cultures were taken [18]. Age-stratified serosurveys 
were performed at each study site to assess seroincidence of ty-
phoid infection. The resulting seroincidence rates will be used 
to validate and provide upper bounds on the incidence rates de-
rived from blood culture surveillance, using host responses as 
a proxy for incidence of infection. Additionally, the serosurveys 
were designed to identify potential chronic carriers of S. Typhi. 
After identifying individuals with a high anti-Vi antibody re-
sponse, follow-up with stool collection and culture was per-
formed to identify stool shedding.
DISCUSSION
Study Similarities
There are important methodological similarities across these 
four studies. Each study includes passive, healthcare facility–
based blood culture surveillance of febrile patients to generate 
crude age-stratified  incidence rate estimates stratified by age. 
Each study team also conducts an HCUS and applies correc-
tion factors to these crude rates to account for the proportion 
of patients from within the catchment area or study population 
seeking care for febrile illness at a study facility. All 4 studies 
make an adjustment for eligible cases missed by the study 
(either patients who met eligibility criteria but were not ap-
proached for enrollment, or who were enrolled and chose not 
to consent, or both), as well as an adjustment for blood culture 
sensitivity. Antimicrobial resistance patterns from sites in all 4 
studies are being analyzed, and whole-genome sequencing of 
selected Salmonella isolates will be available from all studies. 
Cost-of-illness studies are embedded within each of these 
studies, as is screening for chronic typhoid carriage.
The SEAP and SETA studies employ similar methods to cal-
culate incidence, owing in part to efforts coordinated by the 
Scientific Advisory Process for Optimal Research on Typhoid 
Burden of Disease Project (SAPORT, Emory University) group 
to harmonize methods; therefore, the results are more easily 
compared. Both studies generate data on the incidence of se-
vere disease and follow enteric fever patients for at least 6 weeks 
to characterize long-term sequelae. SEFI tier 2 surveillance 
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processes also closely resemble that of SEAP and SETA, al-
though enrollment criteria differ across all 3 studies.
Each of the studies contributes data to advance broader en-
teric fever control objectives. Epidemiological data generated 
from all 4 have been shared with policymakers in relevant coun-
tries in support of decision-making around TCV introduction. 
The impact of TCV deployment is being evaluated or will be 
evaluated at site(s) from 3 of the 4 studies, although the designs 
of these studies and the delivery strategies under evaluation 
differ. A TCV impact assessment is being conducted through 
Kharadar General Hospital in Karachi, Pakistan (SEAP), in re-
sponse to an extensively drug-resistant typhoid outbreak [19]. 
The University of Maryland and University of Oxford with 
Typhoid Vaccine Acceleration Consortium (TyVAC) partners 
are conducting 3 large-scale TCV trials at STRATAA surveil-
lance sites: a cluster-randomized efficacy trial in Bangladesh 
[20] and 2 individually randomized efficacy studies in Nepal 
and Malawi [21, 22]. Interim analysis of the Nepal RCT showed 
that TCV had an 82% vaccine efficacy at 1 year after vaccina-
tion in children < 15 years of age [23]. Leveraging SETA surveil-
lance, the University of Cambridge and partners are planning 2 
TCV studies through the THECA (Typhoid Conjugate Vaccine 
Introductions in Africa) consortium: a cluster-randomized trial 
in Ghana using a similar methodology to the TyVAC trial in 
Bangladesh, as well as a mass-vaccination campaign with co-
hort effectiveness evaluation in the Democratic Republic of 
Congo [24]. In addition, alternatives to blood culture surveil-
lance—namely, seroepidemiology and/or environmental sam-
pling—are being validated at sites in all 4 studies.
Study Differences
There are several differences between the methodologies of these 
studies, which are important to consider when interpreting and 
comparing results. While there is some overlap, the objectives are 
not uniform across the 4 studies. Eligibility criteria differ, as do the 
type, number, and frequency of sample collections. The approach 
to estimating adjusted incidence rates differs between studies, and 
for SETA and SEFI, within study tiers as well. These and other ge-
neral methodological differences are summarized in Table 1.
Each study generates both crude and adjusted incidence 
rates, but the approach to defining population denominators 
and the choice of adjustment factors used differ. Population 
denominators affect both crude and adjusted incidence rate 
calculations, so this distinction is important. The STRATAA 
approach to estimating the population denominator is different 
from the approach used by SEAP, SETA, and SEFI tier 2, as the 
demographic censuses provide precise population denomin-
ators. In SEAP, SETA, and SEFI tier 2, eligible cases come from 
predefined geographic catchment areas, which is arguably less 
precise but also less resource-intensive, and enables surveillance 
to cover larger catchment areas. Each study employs an adjust-
ment for blood culture sensitivity, but STRATAA samples from 
probability distributions informed by a recent meta-analysis of 
blood culture sensitivity by volume of blood acquired per sub-
ject and reported prior antibiotic usage [25], whereas SEAP and 
SETA apply the same correction factor (assuming sensitivity 
of 59%) to each blood culture result [26]. For the healthcare-
seeking adjustment, SETA assumes the same risk of typhoid 
infection for patients who seek care at a study facility and for 
patients who seek care elsewhere, whereas SEAP, SEFI tier 2, 
and STRATAA assume a differential typhoid risk for febrile pa-
tients who seek care at a study facility [13, 27]. SEFI tier 1 does 
not include a healthcare-seeking adjustment, since it employs 
active surveillance.
There are also key differences between these studies based 
on the geographies under surveillance, which are illustrated in 
Figure 1. The STRATAA sites are in densely populated, urban 
areas, whereas SEFI, SETA, and SEAP have a mixture of urban, 
periurban, and rural sites. There are observed differences in 
physician practices around administration of blood culture 
and clinical familiarity with typhoid fever among some South 
Asian sites, and differences in the availability of antimicrobials 
across all study sites. There are differences in preexisting 
capacities across sites to conduct routine blood culture sur-
veillance, and the difference in blood volumes collected and 
antimicrobial usage across sites could lead to variability in the 
sensitivity of results. There is also a great deal of variability in 
accessibility of healthcare facilities, local water and sanitation 
behaviors infrastructure, and fecal sludge management.
There is value in the diversity of these study approaches. 
Some methodological differences are driven by rational, prag-
matic choices made by study investigators that reflect dif-
ferences between sites captured above. Each study addresses 
distinct data gaps, like potential transmission routes, prevalence 
of chronic carriers, and duration of immune response to nat-
ural infection, all of which will potentially inform optimal in-
tervention strategies. Each study includes efforts to validate 1 or 
more low-cost alternatives to blood culture surveillance, which 
means that there is likely to be greater clarity in the near future 
about which approaches, if any, are viable, feasible, and cost-ef-
fective. The diversity of settings under surveillance broadens 
our understanding of the global incidence rates of typhoid fever 
and other invasive Salmonella infections, which will impact pri-
oritization and targeting of combination vaccine development 
efforts. Having more broadly representative genomic data also 
facilitates monitoring the evolution and spread of different anti-
microbial resistance genotypes, which also should inform more 
sophisticated targeting of interventions.
CONCLUSIONS
In a position paper from 2008, the WHO stated that the deploy-
ment of the then-available typhoid vaccines “should be based 
on detailed knowledge of the local epidemiological situation” 
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while simultaneously acknowledging the limitations of the ex-
isting data, particularly for the African continent [7]. In the 
intervening decade, the availability of safe, immunogenic, and 
efficacious TCVs [23, 28] has strengthened the need for ac-
curate burden of disease data across diverse epidemiological 
settings. In this article, we have described the design and meth-
odology of 4 landmark surveillance studies that collectively 
incorporate 44 surveillance facilities, 11 countries, and a total 
population under surveillance of > 20 million people. We argue 
that these studies have made large strides toward achieving the 
2008 targets, and it is hoped that this article provides an im-
portant overview of the methodologies, strengths, and limita-
tions of each individual study. Together, these data will provide 
key stakeholders and country-level decision makers with more 
accurate estimates of disease burden, allowing targeted, timely, 
and cost-effective deployment of new preventative strategies.
The TSAP study demonstrated that there was a significant 
incidence of typhoid fever and iNTS disease in Africa. SETA, 
SEAP, SEFI, and STRATAA are generating data on disease 
transmission, risk factors, cost of illness, and incidence of severe 
disease in Africa and some parts of Asia. Furthermore, these 
studies have provided baseline data in support of ongoing or 
planned phase 3/4 TCV trials. Data from these studies are now 
being used to enable national stakeholders to make informed 
decisions on optimal TCV delivery strategies, and to direct the 
development and prioritization of future Salmonella combina-
tion vaccine approaches. Methodological differences notwith-
standing, each study has contributed important data to advance 
global typhoid control.
Each surveillance study will provide an estimate of disease 
burden for a particular setting at a particular point in time and 
will reflect transmission dynamics specific to a particular set-
ting. We acknowledge that caution should be exercised when ex-
trapolating these figures in an attempt to provide country-level 
estimates of disease burden, as the true distribution of disease 
is likely to display marked intra- and intercountry and temporal 
variation [29]. Furthermore, estimates of disease burden are 
unlikely to be static and will likely change in response to im-
provements or breakdown of sanitation infrastructure and the 
deployment of TCVs. Consideration should be given toward 
the establishment of ongoing surveillance programs to track 
changes in spatial and temporal trends in disease incidence. 
Such programs should be integrated into broader, vaccine-
preventable disease surveillance efforts, and should potentially 
incorporate new, lower-cost alternatives to blood culture sur-
veillance if and when these methods are validated, for maximal 
sustainability.
The updated 2018 WHO position paper on typhoid vaccina-
tion recommends that “endemic countries strengthen the surveil-
lance of typhoid fever in all age groups, and monitor the presence 
of antimicrobial resistant strains of S. Typhi in endemic and epi-
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[10]. Nevertheless, the large surveillance studies described herein 
are unlikely to be funded in perpetuity, and a shift in emphasis 
may need to be made toward strengthening routine national 
surveillance systems with a more targeted remit. It is therefore 
imperative that the existing studies achieve maximal utility by ad-
dressing outstanding questions relating to age-specific incidence, 
transmission, carriage, strain/serovar replacement, and incidence 
post-TCV introduction. In addition, the continued validation of 
alternative low-cost methods for typhoid surveillance at these sites 
could yield substantial benefit to the field.
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